Ark Genomic Revolution ETF (ARKG)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Phone: 212-426-7040
B2iDigital
B2iDigital Jun. 23 at 8:53 PM
eXoZymes (Nasdaq: $EXOZ ) Chief Commercial Officer Damien Perriman will present at Webull’s Biotech Sector webinar on June 25, alongside Envoy Medical and IN8bio. Damien Perriman, Chief Commercial Officer of eXoZymes Inc. (Nasdaq: EXOZ), will present at Webull’s Biotech Sector webinar on June 25 at 2:00 p.m. Eastern, part of the Webull Corporate Connect series that spotlights publicly traded biotech companies for investors. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 eXoZymes is a synthetic biology company that takes enzymes out of the living cell and runs them on their own to manufacture hard-to-make molecules for nutraceutical and pharmaceutical markets. The session gives investors a chance to hear directly from the company’s commercial leadership. • The webinar takes place June 25 at 2:00 p.m. Eastern, 11:00 a.m. Pacific, and registration is free with a Webull account • Perriman presents alongside Brent Lucas, Chief Executive Officer of Envoy Medical, and Will Ho, Chief Executive Officer and co-founder of IN8bio • Perriman leads commercial strategy at eXoZymes, whose cell-free platform uses AI-engineered enzymes to convert low-cost feedstocks into high-value compounds Register for the webinar: https://exozymes.com/blog/webulls-biotech-webinar-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
0 · Reply
charleswindsor111
charleswindsor111 Jun. 23 at 5:34 PM
$ARKG this one is kicking ass, xbi is hitting 52 wk highs also, we need to catch up. Its been long overdue, i wish i had doubled up at 18.00. I just didn't have anymore money left.
0 · Reply
JFDI
JFDI Jun. 22 at 1:15 AM
$ARKG
0 · Reply
capitalthinktank
capitalthinktank Jun. 21 at 10:17 PM
Genomics is starting to look like it’s getting pulled into the broader AI re-rating conversation. $ARKG is trying to push out of a long Stage 1 base - not explosive yet, but the structure is clearly tightening and starting to shift. The idea here is pretty straightforward: if AI tools actually start compressing timelines in drug discovery and biotech workflows, this sector doesn’t re-rate slowly. It tends to move in chunks when sentiment flips. Names I’m watching: $TEM - AI + healthcare infrastructure angle $TWST - synthetic biology platform with heavy data leverage $BEAM - gene editing with longer-duration innovation cycles Still early days, but this is one of those areas where narrative and real productivity gains could start reinforcing each other. Worth keeping on radar.
1 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 21 at 10:12 PM
Genomics / AI-driven biotech is starting to look like one of the next major rotation themes the market is quietly pricing in. $ARKG - pushing out of a long consolidation base, early signs of a potential regime shift in biotech risk appetite What’s interesting here is not just the ETF move - it’s the underlying stock-level strength beginning to emerge beneath it. Key names I’m watching closely in this rotation: $TEM - data-driven healthcare + AI diagnostics, narrative shifting from “early stage” to “scaling execution” $TWST - synthetic biology platform with real industrial + pharma data demand tailwinds $BEAM - precision gene editing exposure tied to next-gen therapeutic pipelines This is how early sector rotation usually looks - ETF breaks first, then selective leaders start to separate. If this continues, genomics could be transitioning from a “speculative AI adjacency” to a true standalone leadership theme. Worth watching closely while it’s still early.
1 · Reply
Nasdaq_Frontier
Nasdaq_Frontier Jun. 21 at 9:50 PM
Genomics set out to be one of the biggest winners from AI? The markets are certainly starting to think so... $ARKG breaking out of a massive stage 1 base Could see a rerate in this sector very quickly.. My favorite stocks: $TEM $TWST $BEAM Watch this sector closely, as it starts to ignite.
0 · Reply
capitalthinktank
capitalthinktank Jun. 21 at 4:49 PM
$ARKG Indicators show a clean breakout from its prolonged consolidation range. With price holding firmly above the high-volume base, the biotech sector looks primed to ignite some much larger upside moves.
0 · Reply
Stockwhisperr
Stockwhisperr Jun. 19 at 5:41 PM
$BFLY Next few weeks will be epic! Some will be speechless, others in disbelief, and many naysayers will tell you why $BFLY ultrasound on chip technology isn’t a game changer. BFLY is no longer a medical device company. It’s a semiconductor company with extraordinary chip and AI technology that will change the world sooner than most expect. BFLY has a pipeline of corporations waiting for Apollo. It doesn’t get much better having major demand for a chip that will be released in 2029! Midjourney is one of many customers that will license $BFLY proprietary chip technology. The multi stream revenues will accelerate in 3-5 years. The train has departed the station, a bit slow but when it gains steam, those standing in front of the train may get crushed! With current stock float and revenues in 2030-2032 today’s valuation at $9.11 isn’t 1.49 billion. It’s closer to 300 million. You can easily conclude a 40X multiple of $330-360. Few Understand 🦋 $ARKG $NVDA $AAPL $STOCKTWITS
2 · Reply
trendtrader6
trendtrader6 Jun. 19 at 2:31 PM
$ARKG weekly chart. Genomics starting to break out of the base. big year coming for this industry imo. $CRSP $EDIT . Any other names to add for Gene editing?
1 · Reply
madnessofcrowds
madnessofcrowds Jun. 19 at 2:23 PM
$ARKG highest weekly close since mid-2023.
0 · Reply
Latest News on ARKG
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Jun 16, 2026, 1:00 AM EDT - 7 days ago

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

IBB XBI GSK NUVL NVS

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

Jan 28, 2025, 6:00 PM EST - 1 year ago

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

ARKB ARKF ARKK ARKQ ARKW

Best Healthcare ETFs To Buy Now

Oct 31, 2024, 2:03 PM EDT - 1 year ago

Best Healthcare ETFs To Buy Now

FXH IXJ VHT XBI XLV

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Jun 14, 2024, 8:00 AM EDT - 2 years ago

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

May 2, 2024, 4:28 PM EDT - 2 years ago

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

AGG ARKB BCI BCIM BITO FBTC HODL

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Jan 18, 2024, 3:23 PM EST - 2 years ago

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

ASHR BLOK CCEF CQQQ DXJ FXI JETS

How to Find the Best Biotech ETFs

Oct 30, 2023, 4:52 PM EDT - 2 years ago

How to Find the Best Biotech ETFs

IBB XBI

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

Jul 17, 2023, 4:57 PM EDT - 3 years ago

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

ARKF ARKK ARKW

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

Mar 21, 2023, 11:52 AM EDT - 3 years ago

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

ARKK ARKW

B2iDigital
B2iDigital Jun. 23 at 8:53 PM
eXoZymes (Nasdaq: $EXOZ ) Chief Commercial Officer Damien Perriman will present at Webull’s Biotech Sector webinar on June 25, alongside Envoy Medical and IN8bio. Damien Perriman, Chief Commercial Officer of eXoZymes Inc. (Nasdaq: EXOZ), will present at Webull’s Biotech Sector webinar on June 25 at 2:00 p.m. Eastern, part of the Webull Corporate Connect series that spotlights publicly traded biotech companies for investors. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 eXoZymes is a synthetic biology company that takes enzymes out of the living cell and runs them on their own to manufacture hard-to-make molecules for nutraceutical and pharmaceutical markets. The session gives investors a chance to hear directly from the company’s commercial leadership. • The webinar takes place June 25 at 2:00 p.m. Eastern, 11:00 a.m. Pacific, and registration is free with a Webull account • Perriman presents alongside Brent Lucas, Chief Executive Officer of Envoy Medical, and Will Ho, Chief Executive Officer and co-founder of IN8bio • Perriman leads commercial strategy at eXoZymes, whose cell-free platform uses AI-engineered enzymes to convert low-cost feedstocks into high-value compounds Register for the webinar: https://exozymes.com/blog/webulls-biotech-webinar-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
0 · Reply
charleswindsor111
charleswindsor111 Jun. 23 at 5:34 PM
$ARKG this one is kicking ass, xbi is hitting 52 wk highs also, we need to catch up. Its been long overdue, i wish i had doubled up at 18.00. I just didn't have anymore money left.
0 · Reply
JFDI
JFDI Jun. 22 at 1:15 AM
$ARKG
0 · Reply
capitalthinktank
capitalthinktank Jun. 21 at 10:17 PM
Genomics is starting to look like it’s getting pulled into the broader AI re-rating conversation. $ARKG is trying to push out of a long Stage 1 base - not explosive yet, but the structure is clearly tightening and starting to shift. The idea here is pretty straightforward: if AI tools actually start compressing timelines in drug discovery and biotech workflows, this sector doesn’t re-rate slowly. It tends to move in chunks when sentiment flips. Names I’m watching: $TEM - AI + healthcare infrastructure angle $TWST - synthetic biology platform with heavy data leverage $BEAM - gene editing with longer-duration innovation cycles Still early days, but this is one of those areas where narrative and real productivity gains could start reinforcing each other. Worth keeping on radar.
1 · Reply
SwingTraderPro1
SwingTraderPro1 Jun. 21 at 10:12 PM
Genomics / AI-driven biotech is starting to look like one of the next major rotation themes the market is quietly pricing in. $ARKG - pushing out of a long consolidation base, early signs of a potential regime shift in biotech risk appetite What’s interesting here is not just the ETF move - it’s the underlying stock-level strength beginning to emerge beneath it. Key names I’m watching closely in this rotation: $TEM - data-driven healthcare + AI diagnostics, narrative shifting from “early stage” to “scaling execution” $TWST - synthetic biology platform with real industrial + pharma data demand tailwinds $BEAM - precision gene editing exposure tied to next-gen therapeutic pipelines This is how early sector rotation usually looks - ETF breaks first, then selective leaders start to separate. If this continues, genomics could be transitioning from a “speculative AI adjacency” to a true standalone leadership theme. Worth watching closely while it’s still early.
1 · Reply
Nasdaq_Frontier
Nasdaq_Frontier Jun. 21 at 9:50 PM
Genomics set out to be one of the biggest winners from AI? The markets are certainly starting to think so... $ARKG breaking out of a massive stage 1 base Could see a rerate in this sector very quickly.. My favorite stocks: $TEM $TWST $BEAM Watch this sector closely, as it starts to ignite.
0 · Reply
capitalthinktank
capitalthinktank Jun. 21 at 4:49 PM
$ARKG Indicators show a clean breakout from its prolonged consolidation range. With price holding firmly above the high-volume base, the biotech sector looks primed to ignite some much larger upside moves.
0 · Reply
Stockwhisperr
Stockwhisperr Jun. 19 at 5:41 PM
$BFLY Next few weeks will be epic! Some will be speechless, others in disbelief, and many naysayers will tell you why $BFLY ultrasound on chip technology isn’t a game changer. BFLY is no longer a medical device company. It’s a semiconductor company with extraordinary chip and AI technology that will change the world sooner than most expect. BFLY has a pipeline of corporations waiting for Apollo. It doesn’t get much better having major demand for a chip that will be released in 2029! Midjourney is one of many customers that will license $BFLY proprietary chip technology. The multi stream revenues will accelerate in 3-5 years. The train has departed the station, a bit slow but when it gains steam, those standing in front of the train may get crushed! With current stock float and revenues in 2030-2032 today’s valuation at $9.11 isn’t 1.49 billion. It’s closer to 300 million. You can easily conclude a 40X multiple of $330-360. Few Understand 🦋 $ARKG $NVDA $AAPL $STOCKTWITS
2 · Reply
trendtrader6
trendtrader6 Jun. 19 at 2:31 PM
$ARKG weekly chart. Genomics starting to break out of the base. big year coming for this industry imo. $CRSP $EDIT . Any other names to add for Gene editing?
1 · Reply
madnessofcrowds
madnessofcrowds Jun. 19 at 2:23 PM
$ARKG highest weekly close since mid-2023.
0 · Reply
B2iDigital
B2iDigital Jun. 19 at 2:15 PM
eXoZymes says its platform can also produce cannabinoids, terpenes, and flavonoids. A May 2026 investor presentation from eXoZymes (Nasdaq: $EXOZ ) put the spotlight on the wider range of compounds its platform can make. Chairman Chris Marlett said cannabinoids are next in line, with terpenes and flavonoids behind them, and that the company is building its patents around the methods used to make these compounds. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 Marlett traced the cannabinoid work back to the company’s earliest days: “So cannabinoids are next. Actually, ironically, it was the first thing we started to make. We started to make cannabinoids. We got grants to make it and we demonstrated that we could get yields.” The presentation also covered: • A platform the company says also extends to terpenes and flavonoids • A strategy to patent the methods used to make natural compounds, plus composition patents on engineered analogs and enzymes • A partnership model spanning contract manufacturers, supplement makers, and pharmaceutical companies • Recognition in scientific and news publications and grant funding the company cites as validation Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology. The company is building a pipeline of natural compounds and engineered analogs across nutraceutical and pharmaceutical applications. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
Stockwhisperr
Stockwhisperr Jun. 19 at 1:32 PM
$BFLY If you want to understand how broken the healthcare system is spend some time on X reading posts by doctors who are dismissive and negative of MidJourney’s ultrasound scanner powered by $BFLY ultrasound on chip technology. Clueless people get left behind in life. Healthcare is the worst industry for change, resistance is huge but $BFLY will be successful with Joe DeVivo as CEO. The world is finally learning about BFLY and in a less than three years 2029 $BFLY will release Apollo which is a game changer for ultrasound, healthcare and many other industries worldwide. I did an analysis and concluded the value of $BFLY is 40X. Yes, that’s 40X from current price. Butterfly is no longer a medical device company, it’s a semiconductor with opportunities to license their technology and generate billions in revenues. The pipeline is full of deals in the making. Most will be in shock and speechless when BFLY hits $330-$365. Few Understand 🦋 $AAPL $NVDA $ARKG $STOCKTWITS
5 · Reply
Lakeview22
Lakeview22 Jun. 18 at 8:32 PM
$ARKG
0 · Reply
madnessofcrowds
madnessofcrowds Jun. 18 at 6:09 PM
$ARKG I'll exercise my 35 calls thank you
0 · Reply
DC729
DC729 Jun. 17 at 5:58 PM
$PSNL hopefully $ARKG can start to catch up to the run in $XBI that’s the only think that drives this stock
1 · Reply
JFDI
JFDI Jun. 17 at 3:58 PM
Cathy I’m on my way! $ARKG $ARKK
1 · Reply
G_krupins
G_krupins Jun. 16 at 11:27 AM
$ARKG nice look to it. Flipped through holdings and like what I see overall. Likely to be a new add for me vs. Last week's low
0 · Reply
oneklim
oneklim Jun. 16 at 4:46 AM
$ARKG looks like arkg will be bouncing between 37 and 32 for a while. IMHO
0 · Reply
Hot_Takes_Zack
Hot_Takes_Zack Jun. 13 at 10:36 PM
$ARKK $ARKG $ARKF $ARKW i know Ark kinda sucks but always loved their business model. The ETFs are not “growth ETFs” in the traditional sense but ARK is not a broken product. I am on their news letter email chains and I must say I’m impressed. I do have a RH account that’s strictly ARK. I expectations to get rich but I love the diversity buckets. Let’s see what happens.
1 · Reply
B2iDigital
B2iDigital Jun. 12 at 5:53 PM
eXoZymes names NCT, a compound tied to fat metabolism, as its lead molecule. NCT, a naturally occurring compound tied to how the body stores and burns fat, is the lead molecule for eXoZymes Inc. (NASDAQ: EXOZ). In a May 2026 investor presentation, Chairman Chris Marlett described how the company is pursuing it for markets such as obesity, type 2 diabetes, and fatty liver on both a nutraceutical and a pharmaceutical track. eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 On what NCT does in the body, Marlett said: “...we see NCT as sort of a master metabolic switch that activates this pathway that really ramps up mitochondrial metabolization of fats and energy in your body and really could address the root of how the body stores and burns stored fat.” Marlett also noted: • Early data the company says points to measurable metabolic effects tied to NCT • A planned over the counter nutraceutical path, with market entry targeted following GRAS work • A parallel pharmaceutical path built around more potent NCT analogs • Interest from pharmaceutical companies exploring complements to GLP-1 therapies, per the company Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris eXoZymes Inc. is a Los Angeles, California based biotechnology company applying AI engineered enzymes to produce natural molecules at scale. Its lead molecule, NCT, is being pursued on both a nutraceutical and a pharmaceutical track. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
ssaudio
ssaudio Jun. 10 at 8:13 PM
$ARKG I thought we had something going there for a blip
0 · Reply
Lakeview22
Lakeview22 Jun. 10 at 5:03 PM
$ARKG adding. maybe next in line for government participation. like drones.
1 · Reply